FOLH1 and prostate carcinoma: However, to our knowledge, the literature contains no additional data regarding the ability of [89Zr]Zr-PSMA-617 PET/CT to characterize as suspicious or non-suspicious for prostate cancer lesions that were indeterminate on conventional PSMA-targeted PET/CT.